Adicet bio, inc. announces proposed public offering

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (“adicet”) (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. the purchase price of each pre-funded warrant will equal the pri.
ACET Ratings Summary
ACET Quant Ranking